Sanaria Inc. With a focus on protecting individuals from Plasmodium falciparum infection, Sanaria's vaccines have demonstrated high efficacy in clinical trials. The ultimate goal is to prevent malaria in individuals and eliminate transmission from communities by combining their vaccines with other malaria control measures.

Sanaria's approach involves using Plasmodium falciparum sporozoites (SPZ) as the basis for their vaccines. This approach has already proven successful, as evidenced by the company's publications and research findings. To facilitate global collaboration, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting biannually, where partners, collaborators, and funders come together to share their work and discuss future research plans.

With a strong commitment to their mission, Sanaria is driven to address the urgent need for malaria vaccines, which cause hundreds of thousands of deaths annually. Their innovative strategies and dedication to collaboration make them a leading force in the development of effective and innovative malaria vaccines